Sensitive Cyp3a Substrates has 14 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ivosidenib, Adagrasib, Givinostat. Patients taking Sensitive Cyp3a Substrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 14
- Contraindicated
- 1
- Major
- 4
- Moderate
- 9
Contraindicated (1)
- Sensitive Cyp3a Substrates + Ivosidenib— Ivosidenib induces CYP3A4, decreasing concentrations of sensitive substrates and risking loss of therapeutic effect. Avo…
Major (4)
- Sensitive Cyp3a Substrates + Adagrasib— Adagrasib increases exposure of CYP3A4 substrates, which may increase the risk of adverse reactions related to these sub…
- Sensitive Cyp3a Substrates + Givinostat— Givinostat is a weak intestinal CYP3A4 inhibitor. Closely monitor when used with oral CYP3A4 sensitive substrates where …
- Sensitive Cyp3a Substrates + Nitisinone— Nitisinone is a moderate CYP2C9 inhibitor that may increase exposure of co-administered drugs metabolized by CYP2C9, req…
- Sensitive Cyp3a Substrates + Olutasidenib— Olutasidenib induces CYP3A and may decrease plasma concentrations of sensitive CYP3A substrates, reducing their efficacy…
Moderate (9)
- Sensitive Cyp3a Substrates + Acoramidis Hydrochloride— Acoramidis inhibits CYP2C9 and may increase substrate concentrations. Monitor patients for signs of increased exposure a…
- Sensitive Cyp3a Substrates + Duvelisib— COPIKTRA increases AUC of sensitive CYP3A4 substrates, which may increase the risk of toxicities. Monitor for signs of t…
- Sensitive Cyp3a Substrates + Finerenone— Finerenone 40 mg is a weak CYP2C8 inhibitor and increases exposure of CYP2C8 substrates; monitor patients more frequentl…
- Sensitive Cyp3a Substrates + Lenacapavir Sodium— YEZTUGO may increase concentrations of sensitive CYP3A substrates, resulting in increased risk of adverse events. Monito…
- Sensitive Cyp3a Substrates + Mitapivat— Mitapivat induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomit…
- Sensitive Cyp3a Substrates + Pitolisant Hydrochloride— WAKIX may reduce effectiveness of sensitive CYP3A4 substrates including hormonal contraceptives.
- Sensitive Cyp3a Substrates + Ribociclib— KISQALI increases exposure of CYP3A4 substrates. Monitor for increased adverse reactions and consider dose reduction of …
- Sensitive Cyp3a Substrates + Suzetrigine— Dosage modification of sensitive CYP3A substrates may be required when initiating or discontinuing JOURNAVX. JOURNAVX is…
- Sensitive Cyp3a Substrates + Viloxazine Hydrochloride— Viloxazine significantly increases total exposure of these substrates, which may increase adverse reaction risk. Not rec…